SFA Therapeutics develops biosynthetic drugs that target specific pathways in chronic inflammatory diseases and cancers by utilizing small molecules that mimic endogenous substances. Their platform technology enhances selectivity and specificity, aiming to improve clinical outcomes while maintaining immune homeostasis.
Funding
$8.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ACAVBFFounders
Product
Problem
Many current treatments for chronic inflammatory diseases and cancers lack specificity, leading to off-target effects and disruption of immune homeostasis. Existing therapies may also fail to address the underlying imbalances in the gut microbiome that contribute to disease progression.
Solution
SFA Therapeutics develops pathway-targeted biosynthetic drugs that selectively modulate disease-specific targets while maintaining immune homeostasis. Their platform technology leverages small molecules that mimic endogenous substances, enhancing selectivity and specificity to improve clinical outcomes. By focusing on the interaction between the gut microbiome and immune function, SFA Therapeutics aims to create innovative oral formulations that offer predictable and consistent clinical results. The company's approach seeks to boost anti-inflammatory responses and downregulate pro-inflammatory cytokines, offering a superior safety profile compared to traditional treatments.
Target Audience
The primary target audience includes patients with autoimmune diseases such as psoriasis and rheumatoid arthritis, various cancers including hepatocellular carcinoma and pancreatic cancer, infectious diseases, and liver diseases like fibrosis and MASH/NASH, as well as those in need of anti-inflammatory adjuvants for CAR-T therapies.
Features
- Small molecule drugs that mimic endogenous substances for enhanced safety
- Pathway-targeted approach for selective interaction with disease-specific targets
- Oral formulations designed for consistent and predictable clinical outcomes
- Modulation of the gut microbiome to address underlying imbalances in chronic diseases
- Focus on boosting anti-inflammatory IL-10 expression and downregulating pro-inflammatory cytokines
- Platform technology applicable to autoimmune diseases, cancers, infectious diseases, and liver diseases